Dinutuximab
Monoclonal antibody
Evidence outlook
Approved: Neuroblastoma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
The registry's posted analysis (3-year EFS 62.9% vs 48.1%, log-rank p=0.1016) differs from the published primary analysis that stopped randomisation for efficacy (2-year EFS 66% vs 46%, P=0.01).
track record: Partial signal
Also approved (1)
- High-risk neuroblastoma in paediatric patients, with GM-CSF, IL-2 and 13-cis-retinoic acid, after at least a partial response to prior first-line multimodal therapy
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00026312 NCT00026312 · Neuroblastoma The trial randomly assigned 226 eligible patients with high-risk neuroblastoma to isotretinoin with or without dinutuximab-based immunotherapy, open-label. The primary analysis met the prespecified early-stopping criteria for efficacy, with event-free survival of 66% versus 46% at 2 years (P=0.01), a hard clinical endpoint. The open-label design limits the grade; the later 3-year analysis posted on the registry (62.9% versus 48.1%, p=0.1016) used longer follow-up. The registry's posted analysis (3-year EFS 62.9% vs 48.1%, log-rank p=0.1016) differs from the published primary analysis that stopped randomisation for efficacy (2-year EFS 66% vs 46%, P=0.01). Registry: NCT00026312 | 3 | Event-Free Survival (EFS) (Three years) 2012-01-12 | Event-free survival at 2 years (primary analysis, NEJM 2010): 66% (±5) with ch14.18 + GM-CSF + IL-2 + isotretinoin vs 46% (±5) with isotretinoin alone, P=0.01; overall survival at 2 years 86% vs 75%, P=0.02. | Partial signal | link ↗ |
View 2 more trials
NCT01041638 NCT01041638 · Neuroblastoma The study was open-label, nonrandomized, and had no control group; 105 patients received a multi-drug regimen containing dinutuximab. Its primary endpoint was descriptive reporting of grade 3–5 toxicities rather than a controlled efficacy comparison, so no primary endpoint comparison was available to be met or missed. Registry: NCT01041638 | 3 | Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome, or Fever). (Up to 6 courses of therapy) 2013-12-31 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
NCT06172296 NCT06172296 · Neuroblastoma Registry: NCT06172296 | 3 | Event free survival (EFS) (Up to 3 years) 2029-12-31 | In progress: results expected 31 Dec 2029 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 1 (1)
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
(9 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Dinutuximab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.